Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29
Refinitiv阅读少于1分钟
Immuneering Corp 
IMRX:
IMMUNEERING TO DISCUSS RECENTLY ANNOUNCED OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON MONDAY, SEPTEMBER 29, 2025
登录或创建永久免费帐户以阅读此新闻